Article Text

other Versions

PDF
Randomized, double-blind, placebo-controlled trial of Intravenous (n-acetylcysteine, selenium, vitamin c) Antioxidant therapy in severe acute pancreatitis.
  1. Ajith K Siriwardena (ajith.siriwardena{at}cmmc.nhs.uk)
  1. Hepatobiliary Unit, Manchester Royal Infirmary, United Kingdom
    1. James M Mason (j.m.mason{at}durham.ac.uk)
    1. School for Health, University of Durham, United Kingdom
      1. Srinivasan Balachandra
      1. Hepatobiliary Unit, Manchester Royal Infirmary, United Kingdom
        1. Anil Bagul (bagula{at}bupa.com)
        1. Hepatobiliary Unit, Manchester Royal Infirmary, United Kingdom
          1. Simon Galloway, Mr (simon.galloway{at}smuht.nwest.nhs.uk)
          1. Department of Upper GI Surgery, Wythenshawe Hospital, United Kingdom
            1. Laura Formela (laura.formela{at}srht.nhs.uk)
            1. Department of Upper GI Surgery, Hope Hospital, Salford, United Kingdom
              1. Jonathan G Hardman (jon.hardman{at}ntlworld.com)
              1. Hepatobiliary Unit, Manchester Royal Infirmary, United Kingdom
                1. Saurabh Jamdar (sjamdar{at}doctors.org.uk)
                1. Hepatobiliary Unit, Manchester Royal Infirmary, United Kingdom

                  Abstract

                  Background: Based on equivocal clinical data, intravenous anti-oxidant therapy has been used for the treatment of severe acute pancreatitis. To date there is no randomized comparison of this therapy in severe acute pancreatitis.

                  Methods: We conducted a randomized, double-blind, placebo controlled trial of intravenous (n- acetylcysteine, selenium, vitamin c) anti-oxidant therapy in patients with predicted severe acute pancreatitis. Forty-three patients were enrolled from three hospitals in the Manchester (UK) area over the period June 2001 to November 2004. Randomisation stratified for APACHE-II score and hospital site, and delivered groups that were similar at baseline.

                  Results: Relative serum levels of antioxidants rose while markers of oxidative stress fell in the active treatment group during the course of the trial. However at 7 days, there was no statistically significant difference in the primary endpoint, organ dysfunction (Antioxidant vs. Placebo: 32% vs. 17%, p=0.33) or any secondary endpoint of organ dysfunction or patient outcome.

                  Conclusions: This study provides no evidence to justify continued use of selenium, n-acetylcysteine, vitamin c- based antioxidant therapy in severe acute pancreatitis. In the context of any future trial design, careful consideration must be given to the risks raised by the greater trend toward adverse outcome in patients in the treatment arm of this study.

                  • acute pancreatitis
                  • randomized controlled trial
                  • anti-oxidant

                  Statistics from Altmetric.com

                  Request permissions

                  If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

                  Linked Articles